Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alnylam Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alnylam Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer | 95,802 | Sep 22, 2026 | 9 |
| Pyott David E I | Director | 1,582 | Jun 3, 2026 | 2 |
| Cravatt Benjamin | Director | – | Jun 3, 2026 | 1 |
| Kellogg Peter N | Director | 1,446 | May 22, 2026 | 1 |
| Hamburg Margaret A | Director | 1,582 | May 22, 2026 | 1 |
| Ausiello Dennis A | Director | 1,582 | May 22, 2026 | 1 |
| Schulman Amy W | Director | 24,049 | May 22, 2026 | 2 |
| Brandicourt Olivier | Director | 1,446 | May 22, 2026 | 1 |
| Arbuckle Stuart A | Director | 671 | May 22, 2026 | 2 |
| Sigal Charles Elliott | Director | 1,446 | May 22, 2026 | 1 |
| Reitan Colleen F | Director | 1,446 | May 22, 2026 | 1 |
| McLaughlin Melissa | Chief Human Resources Officer | 9,443 | Apr 7, 2026 | 1 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 61,805 | Mar 6, 2026 | 6 |
| Garg Pushkal | EVP Chief R&D | 18,693 | Mar 6, 2026 | 6 |
| Tanguler Tolga | EVP, Chief Commercial Officer | 34,297 | Mar 6, 2026 | 6 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 20,569 | Mar 6, 2026 | 7 |
| Supran Bryan | EVP, CLO and Secretary | 14,565 | Mar 4, 2026 | 2 |
| Bonney Michael W | Director | 16,804 | Aug 19, 2025 | 0 |
| Bertozzi Carolyn R | Director | 775 | May 12, 2025 | 0 |
| Hesslein Robert W. | EVP, CLO and Secretary | 8,002 | Mar 5, 2025 | 0 |
| Sharp Phillip A | Director | 0 | Jan 24, 2025 | 0 |
| Franchini Indrani Lall | EVP, CLO & Secretary | 4,133 | Feb 29, 2024 | 0 |
| Vaishnaw Akshay | President | 22,774 | Aug 7, 2023 | 0 |
| Fanucci Marsha | Director | 136 | May 19, 2023 | 0 |
| Paul Steven M | Director | 1,000 | Apr 5, 2022 | 0 |
| Maraganore John | Chief Executive Officer | 227,663 | Dec 23, 2021 | 0 |
| Keating Laurie | EVP, Chief Legal Officer | 5,132 | Aug 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Greenstreet YvonneChief Executive Officer | SSale | −9.58K | $362.86 | −$3.48M | −10.9%78.4K after | 21 lots |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Garg PushkalEVP Chief R&D | SSale | −1.51K | $362.87 | −$547.9K | −6.3%22.5K after | 21 lots |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Poulton Jeffrey V.EVP, Chief Financial Officer | SSale | −2.24K | $310.08 | −$695.2K | −3.6%59.8K after | |
| Feb 17, 2026 (view filing) | Feb 13-17 | 4 days | Fitzgerald Kevin JosephCSO & EVP, Head of Research | SSale | −4.00K | $321.24 | −$1.28M | −15.8%21.3K after | 2 lots10b5-1 |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −1.96K | $310.08 | −$607.4K | −5.8%31.8K after | |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Greenstreet YvonneChief Executive Officer | SSale | −6.96K | $310.08 | −$2.16M | −7.5%85.7K after | |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Garg PushkalEVP Chief R&D | SSale | −2.24K | $310.08 | −$695.2K | −8.3%24.8K after | |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Garg PushkalEVP Chief R&D | SSale | −4.63K | $331.34 | −$1.53M | −17.3%22.1K after | 5 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Greenstreet YvonneChief Executive Officer | SSale | −6.80K | $327.65 | −$2.23M | −6.4%98.6K after | 10 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −1.60K | $327.65 | −$523.6K | −4.2%36.6K after | 10 lots |
| Mar 4, 2026 (view filing) | Mar 2-3 | 2 days | Fitzgerald Kevin JosephCSO & EVP, Head of Research | SSale | −3.25K | $323.62 | −$1.05M | −12.9%21.9K after | 14 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2-3 | 2 days | Garg PushkalEVP Chief R&D | SSale | −3.49K | $323.63 | −$1.13M | −13.0%23.4K after | 14 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Poulton Jeffrey V.EVP, Chief Financial Officer | SSale | −2.21K | $327.65 | −$722.8K | −3.3%64.3K after | 10 lots |
| Mar 6, 2026 (view filing) | Mar 4-5 | 2 days | Fitzgerald Kevin JosephCSO & EVP, Head of Research | SSale | −1.29K | $323.54 | −$417.7K | −5.9%20.6K after | 12 lots10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −2.31K | $323.08 | −$746.0K | −6.3%34.3K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Poulton Jeffrey V.EVP, Chief Financial Officer | SSale | −2.47K | $323.08 | −$797.4K | −3.8%61.8K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Greenstreet YvonneChief Executive Officer | SSale | −2.93K | $323.08 | −$947.6K | −3.0%95.7K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4-5 | 2 days | Garg PushkalEVP Chief R&D | SSale | −4.71K | $323.53 | −$1.52M | −20.1%18.7K after | 12 lots10b5-1 |
| Apr 7, 2026 (view filing) | Apr 2-6 | 5 daysLate | McLaughlin MelissaChief Human Resources Officer | SSale | −3.91K | $325.92 | −$1.27M | −29.3%9.44K after | 14 lots10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Pyott David E IDirector | SSale | −3.83K | $299.18 | −$1.15M | −70.8%1.58K after | 5 lots10b5-1 |